Ablynx N.v.

Sanofi

Sigrid Cornelis

Ann Brigé

Heidi Rommelaere

Eric Lorent

Hendricus Renerus Jacobus Mattheus Hoogenboom

Els Anna Alice Beirnaert

Bruno Dombrecht

Stephanie Staelens

John Edward Park

Timothy Soos

Bernd Weigle

Klaus Erb

Frank Kamiel Delphina Verdonck

Frank Verdonck

Melanie Rieger

Christian Asbrand

Nadine Biesemann

Karen Heyninck

Shanna Van Zwam

Els Beirnaert

Hendricus Renerus Hoogenboom

Hendricus Renerus Jacobus Matteus Hoogenboom

The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-α and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Methods of treating asthma with polypeptides targeting IL-13 and TSLP

The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF&#x3b1; and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.

Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23

Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders

The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

Single variable domain antibodies against OX40L, constructs and therapeutic use

Growing community of inventors

Sint-Martens-Latem, Belgium

Sigrid Cornelis